Beam Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
238 Main St, Cambridge, Massachusetts, 0...Phone Number
(857) 327-8775Website
www.beamtx.comRevenue
$164 MillionStock Symbol
BEAMIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
3
1
5
2
2
About Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing. The company advances research and clinical programs aimed at providing durable treatments for serious diseases, supported by scientific leadership and drug development capabilities. Beam focuses on translating genome editing science into potential lifelong therapies for patients.Explore more
Beam Therapeutics Org Chart
BC
Senior VP, Finance
CD
Strategic Sourcing Vice President, Procuremen...
HM
External Communications Vice President, Inves...
JP
Vice President, Financial Planning & Analysis
GR
Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Beam Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Beam Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Beam Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Beam Therapeutics
Earning: See what the market has to say on Beam Therapeutics recently announced quarterly report
Beam Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Beam Therapeutics launches new products
Check out if Beam Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Beam Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Beam Therapeutics
Compare insights from companies similar to Beam Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Beam Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Beam Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Beam Therapeutics.
Beam Therapeutics financials insights
Gather financial insights about Beam Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$87M
2019
Series B
$135M
2020
Stock Offering
$207M
Stock Offering
$117.5M
2021
Share Placement
$260M
2026
Debt
$500M
Beam Therapeutics Tech Stack
A closer look at the technologies used by Beam Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Events
Open Position
Person-Based
Events, Clinical Operations
Open Position
Beam Therapeutics News & Media
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street expects BEAM stock to pop almost 70% in the next 12 months as therapy programs continue to […]Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 TreatmentBeam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C., May 13, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1...Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Beam Therapeutics
Sign Up For FreeTo access detailed company insights
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing. The company advances research and clinical programs aimed at providing durable treatments for serious diseases, supported by scientific leadership and drug development capabilities. Beam focuses on translating genome editing science into potentia... Read More
